Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 5/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.38 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | F2 | P00734 | 1/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MME | P08473 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4454944 | 1.00 | CYP3A4 (0.44) | CYP3A4CYP2C9RECQLHPGDALDH1A1 | |
| SCHEMBL4454947 | 1.00 | CYP3A4 (0.44) | CYP3A4CYP2C9RECQLHPGDALDH1A1 | |
| SCHEMBL4456248 | 1.00 | CYP3A4 (0.44) | CYP3A4CYP2C9RECQLHPGDALDH1A1 | |
| SCHEMBL4456242 | 1.00 | CYP3A4 (0.44) | CYP3A4CYP2C9RECQLHPGDALDH1A1 | |
| SCHEMBL2861462 | 1.00 | CYP3A4 (0.44) | CYP3A4CYP2C9RECQLHPGDALDH1A1 | |
| SCHEMBL8170512 | 1.00 | CYP3A4 (0.44) | CYP3A4CYP2C9RECQLHPGDALDH1A1 | |
| SCHEMBL2861461 | 1.00 | CYP3A4 (0.44) | CYP3A4CYP2C9RECQLHPGDALDH1A1 | |
| SCHEMBL9048573 | 0.92 | CYP3A4 (0.40) | CYP3A4CYP2C9RECQLHPGDALDH1A1 | |
| SCHEMBL9048580 | 0.92 | CYP3A4 (0.40) | CYP3A4CYP2C9RECQLHPGDALDH1A1 | |
| SCHEMBL27745843 | 0.92 | CYP3A4 (0.40) | CYP3A4CYP2C9RECQLHPGDALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101346352-B | Asymmetric reduction method | KISSEI PHARMACEUTICAL | 2011-04-13 | — | — | CN | claimed |
| US-7847107-B2 | producing (2S)-2-benzyl-3-(cis-hexahydro-2-isoindolinylcarbonyl)propionic acid by catalytic reduction of 2-benzylidene-3-(cis-hexahydro-2-isoindolinylcarbonyl)propionic acid in the presence of an asymmetric catalyst prepared from a pyrrolidinebisphosphine compound | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2010-12-07 | — | — | US | claimed |
| US-20090043110-A1 | Asymmetric Reduction Method | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2009-02-12 | — | — | US | claimed |
| EP-1978016-A1 | ASYMMETRIC REDUCTION METHOD | Kissei Pharmaceutical Co., Ltd. (JP) | 2008-10-08 | — | — | EP | claimed |
| EP-0507534-B1 | Succinic acid compounds | KISSEI PHARMACEUTICAL (JP) | 1996-02-28 | — | — | EP | claimed |
| CN-101346352-B | Asymmetric reduction method | KISSEI PHARMACEUTICAL | 2011-04-13 | — | — | CN | disclosed |
| US-7847107-B2 | producing (2S)-2-benzyl-3-(cis-hexahydro-2-isoindolinylcarbonyl)propionic acid by catalytic reduction of 2-benzylidene-3-(cis-hexahydro-2-isoindolinylcarbonyl)propionic acid in the presence of an asymmetric catalyst prepared from a pyrrolidinebisphosphine compound | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2010-12-07 | — | — | US | disclosed |
| US-7847107-B2 | producing (2S)-2-benzyl-3-(cis-hexahydro-2-isoindolinylcarbonyl)propionic acid by catalytic reduction of 2-benzylidene-3-(cis-hexahydro-2-isoindolinylcarbonyl)propionic acid in the presence of an asymmetric catalyst prepared from a pyrrolidinebisphosphine compound | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2010-12-07 | — | — | US | disclosed |
| EP-1931359-A4 | COMBINATION THERAPY FOR CONTROLLED CARBOHYDRATE DIGESTION | ELIXIR PHARMACEUTICALS INC (US) | 2009-04-01 | — | — | EP | disclosed |
| US-20090043110-A1 | Asymmetric Reduction Method | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2009-02-12 | — | — | US | disclosed |
| US-20090043110-A1 | Asymmetric Reduction Method | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2009-02-12 | — | — | US | disclosed |
| CN-101346352-A | Asymmetric reduction method | KISSEI PHARMACEUTICAL (JP) | 2009-01-14 | — | — | CN | disclosed |
| EP-1931359-A2 | COMBINATION THERAPY FOR CONTROLLED CARBOHYDRATE DIGESTION | Elixir Pharmaceuticals, Inc. (US) | 2008-06-18 | — | — | EP | disclosed |
| WO-2007077818-A1 | ASYMMETRIC REDUCTION METHOD | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2007-07-12 | — | — | WO | disclosed |
| JP-2007176824-A | ASYMMETRIC REDUCTION METHOD | KISSEI PHARMACEUT CO LTD | 2007-07-12 | — | — | JP | disclosed |
| WO-2007033292-A2 | COMBINATION THERAPY FOR CONTROLLED CARBOHYDRATE DIGESTION | ELIXIR PHARMACEUTICALS, INC. (US) | 2007-03-22 | — | — | WO | disclosed |
| US-6133454-A | Method for preparing a substituted perhydroisoindole | ADIR ET COMPAGNIE (FR) | 2000-10-17 | — | — | US | disclosed |
| EP-0507534-B1 | Succinic acid compounds | KISSEI PHARMACEUTICAL (JP) | 1996-02-28 | — | — | EP | disclosed |
| US-5202335-A | Hypoglycemic, antidiabetic agents | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 1993-04-13 | — | — | US | disclosed |
| EP-0507534-A1 | Succinic acid compounds | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 1992-10-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090043110-A1 | Asymmetric Reduction Method | PDXK, BCKDK, AKR1C3 | CYP3A4 1374/4885CYP2C9 935/4885RECQL 3670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.